The effect of psilocybin on personality in patients with major depression -David Erritzoe
Over the last few years, a number of clinical pilot studies have examined the therapeutic potential of psilocybin for a variety of mental health conditions; including anxiety, OCD, smoking and alcohol dependence. David Erritzoe et al have recently
completed a similar feasibility study in treatment-resistant major depression. Based on previous observations in healthy psychedelic naïve volunteers of long-lasting increases in the personality trait “openness” after a single high-dose of psilocybin, Dr. Erritzoe et al speculated that similar changes in personality may occur in patients with major depression after their treatment with psilocybin. This talk will report on a clinical trial involving 19 pa-
tients with treatment-resistant depression who received two doses of psilocybin in an open label pilot study. Significant changes in personality traits, as assessed with pre- and post-treatment personality measurements using the full 240-item NEO-PIR, were observed. These data and their relationships with treatment response will be presented in this talk.
BIOGRAPHY
David Erritzoe is a medical doctor and clinical psychiatrist. After finishing medical school at Copenhagen University, he obtained his PhD on serotonergic neurotransmission in the Center for Integrated Molecular Brain Imaging (CIMBI) in Copenhagen. He is post-doctoral researcher at Imperial College London under the mentorship of Professors Anne Lingford-Hughes and David Nutt. There, he investigates dopaminergic and opioid neurotransmission in addiction. Additionally, he is part of a research programme together with Professor Nutt and Dr Carhart-Harris conducting research in the neurobiology and the treatment potential of MDMA and classic psychedelics. ________
To keep yourself up to date with psychedelic research, come celebrate the latest discoveries in our next in-person ICPR conference organized by the OPEN Foundation: https://icpr-conference.com/
See you there!
Видео The effect of psilocybin on personality in patients with major depression -David Erritzoe канала OPEN Foundation
completed a similar feasibility study in treatment-resistant major depression. Based on previous observations in healthy psychedelic naïve volunteers of long-lasting increases in the personality trait “openness” after a single high-dose of psilocybin, Dr. Erritzoe et al speculated that similar changes in personality may occur in patients with major depression after their treatment with psilocybin. This talk will report on a clinical trial involving 19 pa-
tients with treatment-resistant depression who received two doses of psilocybin in an open label pilot study. Significant changes in personality traits, as assessed with pre- and post-treatment personality measurements using the full 240-item NEO-PIR, were observed. These data and their relationships with treatment response will be presented in this talk.
BIOGRAPHY
David Erritzoe is a medical doctor and clinical psychiatrist. After finishing medical school at Copenhagen University, he obtained his PhD on serotonergic neurotransmission in the Center for Integrated Molecular Brain Imaging (CIMBI) in Copenhagen. He is post-doctoral researcher at Imperial College London under the mentorship of Professors Anne Lingford-Hughes and David Nutt. There, he investigates dopaminergic and opioid neurotransmission in addiction. Additionally, he is part of a research programme together with Professor Nutt and Dr Carhart-Harris conducting research in the neurobiology and the treatment potential of MDMA and classic psychedelics. ________
To keep yourself up to date with psychedelic research, come celebrate the latest discoveries in our next in-person ICPR conference organized by the OPEN Foundation: https://icpr-conference.com/
See you there!
Видео The effect of psilocybin on personality in patients with major depression -David Erritzoe канала OPEN Foundation
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Acute, lasting and antidepressant effects of Ayahuasca - Draulio B. de AraújoInterdisciplinary Conference on Psychedelics Research 2016The Growing Psychedelic Landscape #shorts #PsychedelicResearch #Psychedelics #PsychedelicRenaissanceThe Ultimate Psychedelic CombinationPsychedelic therapy and science - a panel discussionThe Power of Psilocybin | Transforming Lives and Reducing Alcohol AbuseThe Growing Interest and Multifaceted Applications of PsychedelicsExploring the Interface of Reality | Bernardo Kastrup, Ph.D #icpr #shorts #consciousnessUnlocking the Mysteries of Self Transcendence, The Brain's Spiritual Connection #psychedelics #icprVoices of ICPR: Insights from Attendees #shorts #ICPR #psychedelicresearch #psychedelic #scienceAnnouncing ICPR 2020 Online"MDMA Will be a Prescribable Medicine in Two Years" | Interview with PETER GASSER, MDRoland Griffiths reflects on his own mortalityUnlocking the Secrets of the Cortex, the Power of Serotonin 2A Receptors #psychedelicresearch #icprThe Psychedelic Revolution: Interdisciplinary Conference on Psychedelic ResearchProposal for an Integrated Model for Psychedelic Psychotherapy Training - Elizabeth NielsonMDMA for romantic couples - highlights from ICPR2016"We are Starting to Understand How Psychedelics Work in the Brain" | KATRIN PRELLER, PhDClosing speech - Joost Breeksema President of OPENInterdisciplinary Conference on Psychedelic Research (ICPR) 2022 - the short aftermovieProposal: an integrated Model for Psychedelic Therapy Training - Jeffrey Guss